Sickle Cell Disease
Sickle Cell Disease
Advertisement
Zahra Pakbaz, MDSickle Cell Disease | February 27, 2024
Dr. Pakbaz describes some of the difficulties faced by patients with SCD as they switch from pediatric to adult programs.
View More
Patrick DalySickle Cell Disease | February 26, 2024
Reduction of hemolysis significantly predicted postinfusion transduction efficacy in patients with SCD treated with lovo-cel.
Melissa BadamoSickle Cell Disease | February 22, 2024
Exa-cel eliminated RBC transfusions in patients with transfusion-dependent β-thalassemia.
Melissa BadamoSickle Cell Disease | February 21, 2024
Hydroxyurea therapy reduced blood transfusion by 75% among pediatric patients in sub-Saharan Africa with sickle cell anemia.
Patrick DalySickle Cell Disease | February 20, 2024
The European Commission has approved the Conditional Marketing Authorization for exagamglogene autotemcel.
Patrick DalySickle Cell Disease | February 13, 2024
Drs. Grant, Sutin, and Lin discuss their pilot study investigating cerebral hemodynamics in infants with sickle cell disease.
John Strouse, MD, PhDSickle Cell Disease | February 15, 2024
Dr. Pakbaz and Dr. Strouse discuss their experiences practicing classical hematology and where the speciality is heading.
Patrick DalySickle Cell Disease | February 8, 2024
Dr. Pakbaz, from the University of California Irvine, shared data on the value of a dedicated classical hematology clinic.
Patrick DalySickle Cell Disease | January 29, 2024
Most patients with SCD with gallstones reached an advanced stage of gallstones by the time they underwent a cholecystectomy.
Patrick DalySickle Cell Disease | February 8, 2024
Therapy with isoquercetin induced positive reductions in several biomarkers for thromboinflammation in sickle cell disease.
Patrick DalySickle Cell Disease | January 22, 2024
The Saudi Food and Drug Authority granted Marketing Authorization to exa-cel for the treatment of sickle cell disease.
Patrick DalySickle Cell Disease | February 8, 2024
Dr. Pakbaz describes the significant need for specialists dedicated to adult patients with noncancer blood disorders.
Haydar Frangoul, MDSickle Cell Disease | December 30, 2023
Haydar Frangoul, MD, outlined the CLIMB-121 trial data on exagamglogene autotemcel in sickle cell disease.
Katie KoskoSickle Cell Disease | December 14, 2023
Adults with SCD experience HRQOL burden, such as the inability to work, following a vaso-occlusive crisis.
Katie KoskoSickle Cell Disease | December 14, 2023
Pregnancy complications such as cesarean delivery and preeclampsia were more frequent in patients with SCD versus SCD trait.
Katie KoskoSickle Cell Disease | December 14, 2023
Children with sickle cell disease (SCD) had significantly higher heme-oxygenase-1 levels versus adults with SCD.
Katie KoskoSickle Cell Disease | December 14, 2023
Patients with severe SCD had clinically meaningful improvements in health-related quality of life after receiving exa-cel.
Katie KoskoSickle Cell Disease | December 14, 2023
Patients with severe SCD treated with exa-cel achieved no vaso-occlusive crises or inpatient hospital visits.
Cailin ConnerSickle Cell Disease | December 11, 2023
Non-myeloablative versus myeloablative conditioning for HSCT varied in engraftment, hospitalization, and GVHD outcomes.
Cailin ConnerSickle Cell Disease | December 11, 2023
Allotransplantation had "equitable" cost-efficacy in pediatric patients with sickle cell disease in the United States.
Advertisement
Advertisement
Advertisement
Latest News

February 28, 2024